nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—systemic lupus erythematosus	0.355	0.788	CbGaD
Gliclazide—Sulfacetamide—Dapsone—systemic lupus erythematosus	0.174	1	CrCrCtD
Gliclazide—ALB—systemic lupus erythematosus	0.0955	0.212	CbGaD
Gliclazide—ALB—Mycophenolate mofetil—systemic lupus erythematosus	0.0303	0.155	CbGbCtD
Gliclazide—CYP2C9—Leflunomide—systemic lupus erythematosus	0.0264	0.135	CbGbCtD
Gliclazide—ALB—Prednisone—systemic lupus erythematosus	0.0242	0.124	CbGbCtD
Gliclazide—CYP2C19—Dapsone—systemic lupus erythematosus	0.0226	0.116	CbGbCtD
Gliclazide—CYP2C9—Dapsone—systemic lupus erythematosus	0.0188	0.0963	CbGbCtD
Gliclazide—CYP2C19—Prednisone—systemic lupus erythematosus	0.0157	0.0803	CbGbCtD
Gliclazide—CYP2C19—Cyclosporine—systemic lupus erythematosus	0.0149	0.0761	CbGbCtD
Gliclazide—CYP2C9—Cyclosporine—systemic lupus erythematosus	0.0124	0.0633	CbGbCtD
Gliclazide—ALB—Methotrexate—systemic lupus erythematosus	0.0121	0.0622	CbGbCtD
Gliclazide—CYP2C19—Dexamethasone—systemic lupus erythematosus	0.0098	0.0501	CbGbCtD
Gliclazide—CYP2C9—Dexamethasone—systemic lupus erythematosus	0.00815	0.0417	CbGbCtD
Gliclazide—CYP2C9—cardial valve—systemic lupus erythematosus	0.00764	0.318	CbGeAlD
Gliclazide—CYP2C19—urine—systemic lupus erythematosus	0.00213	0.0885	CbGeAlD
Gliclazide—CYP2C9—urine—systemic lupus erythematosus	0.00165	0.0686	CbGeAlD
Gliclazide—VEGFA—nephron tubule—systemic lupus erythematosus	0.00151	0.0627	CbGeAlD
Gliclazide—VEGFA—cortex of kidney—systemic lupus erythematosus	0.00129	0.0537	CbGeAlD
Gliclazide—CYP2C19—blood plasma—systemic lupus erythematosus	0.00111	0.0462	CbGeAlD
Gliclazide—VEGFA—tendon—systemic lupus erythematosus	0.00107	0.0445	CbGeAlD
Gliclazide—VEGFA—bone marrow—systemic lupus erythematosus	0.00103	0.0431	CbGeAlD
Gliclazide—VEGFA—lung—systemic lupus erythematosus	0.000938	0.0391	CbGeAlD
Gliclazide—ABCC8—kidney—systemic lupus erythematosus	0.000872	0.0363	CbGeAlD
Gliclazide—CYP2C9—blood plasma—systemic lupus erythematosus	0.00086	0.0358	CbGeAlD
Gliclazide—KCNJ11—lymphoid tissue—systemic lupus erythematosus	0.000813	0.0339	CbGeAlD
Gliclazide—KCNJ11—tendon—systemic lupus erythematosus	0.000764	0.0318	CbGeAlD
Gliclazide—KCNJ11—nervous system—systemic lupus erythematosus	0.000621	0.0259	CbGeAlD
Gliclazide—KCNJ11—central nervous system—systemic lupus erythematosus	0.000598	0.0249	CbGeAlD
Gliclazide—Glipizide—PPARG—systemic lupus erythematosus	0.000591	0.845	CrCbGaD
Gliclazide—ABCC8—nervous system—systemic lupus erythematosus	0.000572	0.0238	CbGeAlD
Gliclazide—ABCC8—central nervous system—systemic lupus erythematosus	0.000551	0.0229	CbGeAlD
Gliclazide—VEGFA—Dexamethasone—Hydrocortisone—systemic lupus erythematosus	0.000205	0.0912	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Hydrocortisone—systemic lupus erythematosus	0.000205	0.0912	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Methylprednisolone—systemic lupus erythematosus	0.000193	0.0861	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Methylprednisolone—systemic lupus erythematosus	0.000193	0.0861	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Betamethasone—systemic lupus erythematosus	0.00019	0.0847	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Dexamethasone—systemic lupus erythematosus	0.00019	0.0847	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Triamcinolone—systemic lupus erythematosus	0.000186	0.0828	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Triamcinolone—systemic lupus erythematosus	0.000186	0.0828	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Prednisone—systemic lupus erythematosus	0.000176	0.0786	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisone—systemic lupus erythematosus	0.000176	0.0786	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Prednisolone—systemic lupus erythematosus	0.000172	0.0767	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisolone—systemic lupus erythematosus	0.000172	0.0767	CbGdCrCtD
Gliclazide—ALB—Platelet degranulation—CLU—systemic lupus erythematosus	0.00013	0.00394	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—JAK1—systemic lupus erythematosus	0.00013	0.00394	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—HIST2H2AC—systemic lupus erythematosus	0.00013	0.00393	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic lupus erythematosus	0.000128	0.00387	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—GADD45A—systemic lupus erythematosus	0.000125	0.00378	CbGpPWpGaD
Gliclazide—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	0.000124	0.00377	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—CLU—systemic lupus erythematosus	0.000124	0.00376	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IL2—systemic lupus erythematosus	0.000123	0.00373	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—CDKN1B—systemic lupus erythematosus	0.000118	0.00357	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—JUNB—systemic lupus erythematosus	0.000118	0.00356	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—ALB—systemic lupus erythematosus	0.000118	0.00356	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—CDKN1B—systemic lupus erythematosus	0.000115	0.00348	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—ETS1—systemic lupus erythematosus	0.000113	0.00342	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—ALB—systemic lupus erythematosus	0.000112	0.00339	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—TGFB1—systemic lupus erythematosus	0.000112	0.00338	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC15A4—systemic lupus erythematosus	0.000112	0.00338	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—IL6—systemic lupus erythematosus	0.000111	0.00336	CbGpPWpGaD
Gliclazide—Glyburide—ALB—systemic lupus erythematosus	0.000109	0.155	CrCbGaD
Gliclazide—VEGFA—Allograft Rejection—IFNG—systemic lupus erythematosus	0.000108	0.00328	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—TNF—systemic lupus erythematosus	0.000108	0.00327	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—MMP9—systemic lupus erythematosus	0.000108	0.00326	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	0.000107	0.00325	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL10—systemic lupus erythematosus	0.000107	0.00323	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—JAK1—systemic lupus erythematosus	0.000105	0.00317	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—RXRA—systemic lupus erythematosus	0.000103	0.00312	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—EP300—systemic lupus erythematosus	9.98e-05	0.00302	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—RASGRP1—systemic lupus erythematosus	9.96e-05	0.00301	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—NR3C1—systemic lupus erythematosus	9.89e-05	0.00299	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—LYN—systemic lupus erythematosus	9.77e-05	0.00296	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL2—systemic lupus erythematosus	9.63e-05	0.00291	CbGpPWpGaD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—NR3C1—systemic lupus erythematosus	9.61e-05	0.00291	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ITGAX—systemic lupus erythematosus	9.47e-05	0.00287	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—F3—systemic lupus erythematosus	9.34e-05	0.00282	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—TYK2—systemic lupus erythematosus	9.08e-05	0.00275	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—NOS3—systemic lupus erythematosus	8.91e-05	0.0027	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—TGFB1—systemic lupus erythematosus	8.89e-05	0.00269	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—TYK2—systemic lupus erythematosus	8.57e-05	0.00259	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—FASLG—systemic lupus erythematosus	8.45e-05	0.00256	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—CLU—systemic lupus erythematosus	8.44e-05	0.00255	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—IL6—systemic lupus erythematosus	8.43e-05	0.00255	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—NOS3—systemic lupus erythematosus	8.41e-05	0.00254	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—PTPRC—systemic lupus erythematosus	8.36e-05	0.00253	CbGpPWpGaD
Gliclazide—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	8.26e-05	0.0025	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—P2RY12—systemic lupus erythematosus	8.18e-05	0.00247	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—FAS—systemic lupus erythematosus	8.15e-05	0.00247	CbGpPWpGaD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—F2—systemic lupus erythematosus	8.06e-05	0.00244	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP9—systemic lupus erythematosus	7.93e-05	0.0024	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—CRP—systemic lupus erythematosus	7.76e-05	0.00235	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—JAK1—systemic lupus erythematosus	7.72e-05	0.00234	CbGpPWpGaD
Gliclazide—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	7.53e-05	0.00228	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—CSK—systemic lupus erythematosus	7.53e-05	0.00228	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SELE—systemic lupus erythematosus	7.53e-05	0.00228	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—TGFB1—systemic lupus erythematosus	7.51e-05	0.00227	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	7.49e-05	0.00227	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—TGFB1—systemic lupus erythematosus	7.43e-05	0.00225	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL4—systemic lupus erythematosus	7.3e-05	0.00221	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IL6—systemic lupus erythematosus	7.25e-05	0.00219	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL2RA—systemic lupus erythematosus	7.21e-05	0.00218	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—F2—systemic lupus erythematosus	7.16e-05	0.00217	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic lupus erythematosus	7.08e-05	0.00214	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ITGAM—systemic lupus erythematosus	7.08e-05	0.00214	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—TNF—systemic lupus erythematosus	7.01e-05	0.00212	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—LYN—systemic lupus erythematosus	6.97e-05	0.00211	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—LYN—systemic lupus erythematosus	6.84e-05	0.00207	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SH2B3—systemic lupus erythematosus	6.71e-05	0.00203	CbGpPWpGaD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	6.69e-05	0.00202	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—CCL2—systemic lupus erythematosus	6.38e-05	0.00193	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—NAT2—systemic lupus erythematosus	6.34e-05	0.00192	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—CRP—systemic lupus erythematosus	6.31e-05	0.00191	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—F2—systemic lupus erythematosus	6.28e-05	0.0019	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—NAT2—systemic lupus erythematosus	6.25e-05	0.00189	CbGpPWpGaD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	6.1e-05	0.00185	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—PTPRC—systemic lupus erythematosus	5.97e-05	0.00181	CbGpPWpGaD
Gliclazide—Hypertension—Dexamethasone—systemic lupus erythematosus	5.9e-05	0.000494	CcSEcCtD
Gliclazide—Hypertension—Betamethasone—systemic lupus erythematosus	5.9e-05	0.000494	CcSEcCtD
Gliclazide—Paraesthesia—Hydrocortisone—systemic lupus erythematosus	5.87e-05	0.000491	CcSEcCtD
Gliclazide—Gastrointestinal pain—Mycophenolate mofetil—systemic lupus erythematosus	5.86e-05	0.00049	CcSEcCtD
Gliclazide—Urticaria—Cyclosporine—systemic lupus erythematosus	5.84e-05	0.000488	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—F2—systemic lupus erythematosus	5.83e-05	0.00176	CbGpPWpGaD
Gliclazide—Myalgia—Betamethasone—systemic lupus erythematosus	5.82e-05	0.000487	CcSEcCtD
Gliclazide—Myalgia—Dexamethasone—systemic lupus erythematosus	5.82e-05	0.000487	CcSEcCtD
Gliclazide—Body temperature increased—Cyclosporine—systemic lupus erythematosus	5.81e-05	0.000486	CcSEcCtD
Gliclazide—Abdominal pain—Cyclosporine—systemic lupus erythematosus	5.81e-05	0.000486	CcSEcCtD
Gliclazide—Anxiety—Dexamethasone—systemic lupus erythematosus	5.8e-05	0.000485	CcSEcCtD
Gliclazide—Anxiety—Betamethasone—systemic lupus erythematosus	5.8e-05	0.000485	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—NAT2—systemic lupus erythematosus	5.78e-05	0.00175	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—CLU—systemic lupus erythematosus	5.78e-05	0.00175	CbGpPWpGaD
Gliclazide—Discomfort—Dexamethasone—systemic lupus erythematosus	5.75e-05	0.000481	CcSEcCtD
Gliclazide—Discomfort—Betamethasone—systemic lupus erythematosus	5.75e-05	0.000481	CcSEcCtD
Gliclazide—Dyspepsia—Hydrocortisone—systemic lupus erythematosus	5.75e-05	0.000481	CcSEcCtD
Gliclazide—Hypotension—Methylprednisolone—systemic lupus erythematosus	5.73e-05	0.00048	CcSEcCtD
Gliclazide—Pain—Prednisolone—systemic lupus erythematosus	5.72e-05	0.000478	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—systemic lupus erythematosus	5.72e-05	0.000478	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—NAT2—systemic lupus erythematosus	5.7e-05	0.00173	CbGpPWpGaD
Gliclazide—Urticaria—Mycophenolate mofetil—systemic lupus erythematosus	5.7e-05	0.000476	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—JAK1—systemic lupus erythematosus	5.69e-05	0.00172	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	5.68e-05	0.00172	CbGpPWpGaD
Gliclazide—Pharyngitis—Methotrexate—systemic lupus erythematosus	5.67e-05	0.000475	CcSEcCtD
Gliclazide—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	5.67e-05	0.000474	CcSEcCtD
Gliclazide—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	5.67e-05	0.000474	CcSEcCtD
Gliclazide—Nausea—Leflunomide—systemic lupus erythematosus	5.66e-05	0.000473	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	5.64e-05	0.000472	CcSEcCtD
Gliclazide—Fatigue—Hydrocortisone—systemic lupus erythematosus	5.63e-05	0.000471	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—ADIPOQ—systemic lupus erythematosus	5.63e-05	0.0017	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	5.6e-05	0.000469	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—P2RY12—systemic lupus erythematosus	5.6e-05	0.00169	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	5.59e-05	0.000468	CcSEcCtD
Gliclazide—Pain—Hydrocortisone—systemic lupus erythematosus	5.59e-05	0.000467	CcSEcCtD
Gliclazide—Insomnia—Triamcinolone—systemic lupus erythematosus	5.56e-05	0.000465	CcSEcCtD
Gliclazide—Insomnia—Methylprednisolone—systemic lupus erythematosus	5.55e-05	0.000464	CcSEcCtD
Gliclazide—Infection—Dexamethasone—systemic lupus erythematosus	5.54e-05	0.000464	CcSEcCtD
Gliclazide—Infection—Betamethasone—systemic lupus erythematosus	5.54e-05	0.000464	CcSEcCtD
Gliclazide—Ill-defined disorder—Prednisone—systemic lupus erythematosus	5.53e-05	0.000462	CcSEcCtD
Gliclazide—Paraesthesia—Triamcinolone—systemic lupus erythematosus	5.52e-05	0.000462	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisolone—systemic lupus erythematosus	5.51e-05	0.000461	CcSEcCtD
Gliclazide—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	5.51e-05	0.000461	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—systemic lupus erythematosus	5.51e-05	0.000461	CcSEcCtD
Gliclazide—Anaemia—Prednisone—systemic lupus erythematosus	5.5e-05	0.00046	CcSEcCtD
Gliclazide—Dyspnoea—Triamcinolone—systemic lupus erythematosus	5.48e-05	0.000459	CcSEcCtD
Gliclazide—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	5.47e-05	0.000458	CcSEcCtD
Gliclazide—Nervous system disorder—Betamethasone—systemic lupus erythematosus	5.47e-05	0.000458	CcSEcCtD
Gliclazide—Agitation—Prednisone—systemic lupus erythematosus	5.47e-05	0.000458	CcSEcCtD
Gliclazide—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	5.46e-05	0.000457	CcSEcCtD
Gliclazide—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	5.46e-05	0.000457	CcSEcCtD
Gliclazide—Tachycardia—Dexamethasone—systemic lupus erythematosus	5.45e-05	0.000456	CcSEcCtD
Gliclazide—Tachycardia—Betamethasone—systemic lupus erythematosus	5.45e-05	0.000456	CcSEcCtD
Gliclazide—Angioedema—Prednisone—systemic lupus erythematosus	5.44e-05	0.000455	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—IFNG—systemic lupus erythematosus	5.43e-05	0.00164	CbGpPWpGaD
Gliclazide—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	5.42e-05	0.000453	CcSEcCtD
Gliclazide—Dyspepsia—Triamcinolone—systemic lupus erythematosus	5.41e-05	0.000453	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—systemic lupus erythematosus	5.41e-05	0.000452	CcSEcCtD
Gliclazide—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	5.4e-05	0.000452	CcSEcCtD
Gliclazide—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	5.4e-05	0.000451	CcSEcCtD
Gliclazide—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	5.4e-05	0.000451	CcSEcCtD
Gliclazide—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	5.38e-05	0.00045	CcSEcCtD
Gliclazide—Malaise—Prednisone—systemic lupus erythematosus	5.37e-05	0.000449	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—systemic lupus erythematosus	5.34e-05	0.000447	CcSEcCtD
Gliclazide—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	5.34e-05	0.000447	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—systemic lupus erythematosus	5.33e-05	0.000446	CcSEcCtD
Gliclazide—Urticaria—Prednisolone—systemic lupus erythematosus	5.31e-05	0.000444	CcSEcCtD
Gliclazide—Fatigue—Triamcinolone—systemic lupus erythematosus	5.3e-05	0.000443	CcSEcCtD
Gliclazide—Fatigue—Methylprednisolone—systemic lupus erythematosus	5.29e-05	0.000442	CcSEcCtD
Gliclazide—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	5.28e-05	0.000442	CcSEcCtD
Gliclazide—Asthenia—Cyclosporine—systemic lupus erythematosus	5.27e-05	0.000441	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—IFNA1—systemic lupus erythematosus	5.27e-05	0.00159	CbGpPWpGaD
Gliclazide—Pain—Triamcinolone—systemic lupus erythematosus	5.26e-05	0.00044	CcSEcCtD
Gliclazide—Loss of consciousness—Prednisone—systemic lupus erythematosus	5.23e-05	0.000438	CcSEcCtD
Gliclazide—Hypotension—Dexamethasone—systemic lupus erythematosus	5.21e-05	0.000436	CcSEcCtD
Gliclazide—Hypotension—Betamethasone—systemic lupus erythematosus	5.21e-05	0.000436	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—ALB—systemic lupus erythematosus	5.21e-05	0.00158	CbGpPWpGaD
Gliclazide—Pruritus—Cyclosporine—systemic lupus erythematosus	5.2e-05	0.000435	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—CCL2—systemic lupus erythematosus	5.19e-05	0.00157	CbGpPWpGaD
Gliclazide—Urticaria—Hydrocortisone—systemic lupus erythematosus	5.19e-05	0.000434	CcSEcCtD
Gliclazide—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	5.16e-05	0.000432	CcSEcCtD
Gliclazide—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	5.16e-05	0.000432	CcSEcCtD
Gliclazide—Convulsion—Prednisone—systemic lupus erythematosus	5.16e-05	0.000432	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—CSK—systemic lupus erythematosus	5.15e-05	0.00156	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—EP300—systemic lupus erythematosus	5.14e-05	0.00156	CbGpPWpGaD
Gliclazide—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	5.14e-05	0.00043	CcSEcCtD
Gliclazide—Hypertension—Prednisone—systemic lupus erythematosus	5.14e-05	0.00043	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—RASGRP1—systemic lupus erythematosus	5.13e-05	0.00155	CbGpPWpGaD
Gliclazide—Chills—Methotrexate—systemic lupus erythematosus	5.13e-05	0.000429	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTGS2—systemic lupus erythematosus	5.13e-05	0.00155	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	5.08e-05	0.000425	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	5.08e-05	0.000425	CcSEcCtD
Gliclazide—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	5.07e-05	0.000424	CcSEcCtD
Gliclazide—Arthralgia—Prednisone—systemic lupus erythematosus	5.07e-05	0.000424	CcSEcCtD
Gliclazide—Myalgia—Prednisone—systemic lupus erythematosus	5.07e-05	0.000424	CcSEcCtD
Gliclazide—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	5.07e-05	0.000424	CcSEcCtD
Gliclazide—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	5.06e-05	0.000423	CcSEcCtD
Gliclazide—Anxiety—Prednisone—systemic lupus erythematosus	5.05e-05	0.000423	CcSEcCtD
Gliclazide—Insomnia—Betamethasone—systemic lupus erythematosus	5.05e-05	0.000422	CcSEcCtD
Gliclazide—Insomnia—Dexamethasone—systemic lupus erythematosus	5.05e-05	0.000422	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	5.03e-05	0.000421	CcSEcCtD
Gliclazide—Diarrhoea—Cyclosporine—systemic lupus erythematosus	5.03e-05	0.000421	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	5.02e-05	0.00042	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—CRP—systemic lupus erythematosus	5.01e-05	0.00152	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—EP300—systemic lupus erythematosus	5.01e-05	0.00152	CbGpPWpGaD
Gliclazide—Paraesthesia—Dexamethasone—systemic lupus erythematosus	5.01e-05	0.000419	CcSEcCtD
Gliclazide—Paraesthesia—Betamethasone—systemic lupus erythematosus	5.01e-05	0.000419	CcSEcCtD
Gliclazide—Discomfort—Prednisone—systemic lupus erythematosus	5.01e-05	0.000419	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—systemic lupus erythematosus	5.01e-05	0.000419	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—systemic lupus erythematosus	4.98e-05	0.000416	CcSEcCtD
Gliclazide—Erythema—Methotrexate—systemic lupus erythematosus	4.98e-05	0.000416	CcSEcCtD
Gliclazide—Hypersensitivity—Prednisolone—systemic lupus erythematosus	4.93e-05	0.000412	CcSEcCtD
Gliclazide—Dyspepsia—Betamethasone—systemic lupus erythematosus	4.91e-05	0.000411	CcSEcCtD
Gliclazide—Dyspepsia—Dexamethasone—systemic lupus erythematosus	4.91e-05	0.000411	CcSEcCtD
Gliclazide—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	4.91e-05	0.00041	CcSEcCtD
Gliclazide—Urticaria—Triamcinolone—systemic lupus erythematosus	4.89e-05	0.000409	CcSEcCtD
Gliclazide—Urticaria—Methylprednisolone—systemic lupus erythematosus	4.88e-05	0.000408	CcSEcCtD
Gliclazide—Body temperature increased—Triamcinolone—systemic lupus erythematosus	4.86e-05	0.000407	CcSEcCtD
Gliclazide—Dizziness—Cyclosporine—systemic lupus erythematosus	4.86e-05	0.000406	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	4.85e-05	0.00147	CbGpPWpGaD
Gliclazide—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	4.85e-05	0.000406	CcSEcCtD
Gliclazide—Infection—Prednisone—systemic lupus erythematosus	4.83e-05	0.000404	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—RXRA—systemic lupus erythematosus	4.83e-05	0.00146	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	4.82e-05	0.000403	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	4.82e-05	0.000403	CcSEcCtD
Gliclazide—Back pain—Methotrexate—systemic lupus erythematosus	4.81e-05	0.000403	CcSEcCtD
Gliclazide—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	4.81e-05	0.000402	CcSEcCtD
Gliclazide—Fatigue—Betamethasone—systemic lupus erythematosus	4.81e-05	0.000402	CcSEcCtD
Gliclazide—Fatigue—Dexamethasone—systemic lupus erythematosus	4.81e-05	0.000402	CcSEcCtD
Gliclazide—Pain—Betamethasone—systemic lupus erythematosus	4.77e-05	0.000399	CcSEcCtD
Gliclazide—Pain—Dexamethasone—systemic lupus erythematosus	4.77e-05	0.000399	CcSEcCtD
Gliclazide—Nervous system disorder—Prednisone—systemic lupus erythematosus	4.77e-05	0.000399	CcSEcCtD
Gliclazide—CYP2C19—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	4.74e-05	0.00144	CbGpPWpGaD
Gliclazide—Tachycardia—Prednisone—systemic lupus erythematosus	4.74e-05	0.000397	CcSEcCtD
Gliclazide—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	4.74e-05	0.000397	CcSEcCtD
Gliclazide—Skin disorder—Prednisone—systemic lupus erythematosus	4.72e-05	0.000395	CcSEcCtD
Gliclazide—Hyperhidrosis—Prednisone—systemic lupus erythematosus	4.7e-05	0.000393	CcSEcCtD
Gliclazide—Asthenia—Hydrocortisone—systemic lupus erythematosus	4.69e-05	0.000392	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—LYN—systemic lupus erythematosus	4.68e-05	0.00142	CbGpPWpGaD
Gliclazide—Vomiting—Cyclosporine—systemic lupus erythematosus	4.67e-05	0.000391	CcSEcCtD
Gliclazide—Rash—Cyclosporine—systemic lupus erythematosus	4.63e-05	0.000388	CcSEcCtD
Gliclazide—Dermatitis—Cyclosporine—systemic lupus erythematosus	4.63e-05	0.000387	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—F2—systemic lupus erythematosus	4.63e-05	0.0014	CbGpPWpGaD
Gliclazide—Pruritus—Hydrocortisone—systemic lupus erythematosus	4.62e-05	0.000386	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	4.62e-05	0.000386	CcSEcCtD
Gliclazide—Headache—Cyclosporine—systemic lupus erythematosus	4.6e-05	0.000385	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—systemic lupus erythematosus	4.6e-05	0.000385	CcSEcCtD
Gliclazide—Feeling abnormal—Betamethasone—systemic lupus erythematosus	4.6e-05	0.000385	CcSEcCtD
Gliclazide—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	4.6e-05	0.000385	CcSEcCtD
Gliclazide—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	4.56e-05	0.000382	CcSEcCtD
Gliclazide—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	4.56e-05	0.000382	CcSEcCtD
Gliclazide—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	4.56e-05	0.000381	CcSEcCtD
Gliclazide—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	4.53e-05	0.000379	CcSEcCtD
Gliclazide—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	4.52e-05	0.000378	CcSEcCtD
Gliclazide—Rash—Mycophenolate mofetil—systemic lupus erythematosus	4.52e-05	0.000378	CcSEcCtD
Gliclazide—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	4.52e-05	0.000378	CcSEcCtD
Gliclazide—Headache—Mycophenolate mofetil—systemic lupus erythematosus	4.49e-05	0.000376	CcSEcCtD
Gliclazide—Malaise—Methotrexate—systemic lupus erythematosus	4.49e-05	0.000375	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	4.48e-05	0.00136	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	4.48e-05	0.00136	CbGpPWpGaD
Gliclazide—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	4.47e-05	0.000374	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—systemic lupus erythematosus	4.45e-05	0.000373	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—IL6—systemic lupus erythematosus	4.44e-05	0.00134	CbGpPWpGaD
Gliclazide—Urticaria—Dexamethasone—systemic lupus erythematosus	4.43e-05	0.000371	CcSEcCtD
Gliclazide—Urticaria—Betamethasone—systemic lupus erythematosus	4.43e-05	0.000371	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	4.43e-05	0.00037	CcSEcCtD
Gliclazide—Dizziness—Prednisolone—systemic lupus erythematosus	4.42e-05	0.00037	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—IFNG—systemic lupus erythematosus	4.41e-05	0.00134	CbGpPWpGaD
Gliclazide—Asthenia—Triamcinolone—systemic lupus erythematosus	4.41e-05	0.000369	CcSEcCtD
Gliclazide—Body temperature increased—Dexamethasone—systemic lupus erythematosus	4.41e-05	0.000369	CcSEcCtD
Gliclazide—Body temperature increased—Betamethasone—systemic lupus erythematosus	4.41e-05	0.000369	CcSEcCtD
Gliclazide—Abdominal pain—Dexamethasone—systemic lupus erythematosus	4.41e-05	0.000369	CcSEcCtD
Gliclazide—Abdominal pain—Betamethasone—systemic lupus erythematosus	4.41e-05	0.000369	CcSEcCtD
Gliclazide—Asthenia—Methylprednisolone—systemic lupus erythematosus	4.4e-05	0.000368	CcSEcCtD
Gliclazide—Insomnia—Prednisone—systemic lupus erythematosus	4.4e-05	0.000368	CcSEcCtD
Gliclazide—Nausea—Cyclosporine—systemic lupus erythematosus	4.37e-05	0.000365	CcSEcCtD
Gliclazide—Paraesthesia—Prednisone—systemic lupus erythematosus	4.36e-05	0.000365	CcSEcCtD
Gliclazide—Pruritus—Triamcinolone—systemic lupus erythematosus	4.35e-05	0.000364	CcSEcCtD
Gliclazide—Cough—Methotrexate—systemic lupus erythematosus	4.34e-05	0.000363	CcSEcCtD
Gliclazide—Pruritus—Methylprednisolone—systemic lupus erythematosus	4.34e-05	0.000363	CcSEcCtD
Gliclazide—CYP2C9—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	4.33e-05	0.00131	CbGpPWpGaD
Gliclazide—Dizziness—Hydrocortisone—systemic lupus erythematosus	4.32e-05	0.000361	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—systemic lupus erythematosus	4.31e-05	0.000361	CcSEcCtD
Gliclazide—Dyspepsia—Prednisone—systemic lupus erythematosus	4.28e-05	0.000358	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	4.26e-05	0.00129	CbGpPWpGaD
Gliclazide—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	4.26e-05	0.000356	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—systemic lupus erythematosus	4.24e-05	0.000354	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—systemic lupus erythematosus	4.24e-05	0.000354	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—systemic lupus erythematosus	4.24e-05	0.000354	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL2—systemic lupus erythematosus	4.23e-05	0.00128	CbGpPWpGaD
Gliclazide—Rash—Prednisolone—systemic lupus erythematosus	4.22e-05	0.000353	CcSEcCtD
Gliclazide—Dermatitis—Prednisolone—systemic lupus erythematosus	4.21e-05	0.000352	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	4.21e-05	0.000352	CcSEcCtD
Gliclazide—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	4.2e-05	0.000351	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—IL6—systemic lupus erythematosus	4.19e-05	0.00127	CbGpPWpGaD
Gliclazide—Fatigue—Prednisone—systemic lupus erythematosus	4.19e-05	0.00035	CcSEcCtD
Gliclazide—Headache—Prednisolone—systemic lupus erythematosus	4.19e-05	0.00035	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—systemic lupus erythematosus	4.19e-05	0.00035	CcSEcCtD
Gliclazide—Constipation—Prednisone—systemic lupus erythematosus	4.16e-05	0.000348	CcSEcCtD
Gliclazide—Vomiting—Hydrocortisone—systemic lupus erythematosus	4.15e-05	0.000347	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—CCL2—systemic lupus erythematosus	4.12e-05	0.00125	CbGpPWpGaD
Gliclazide—Rash—Hydrocortisone—systemic lupus erythematosus	4.12e-05	0.000344	CcSEcCtD
Gliclazide—Dermatitis—Hydrocortisone—systemic lupus erythematosus	4.11e-05	0.000344	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—systemic lupus erythematosus	4.1e-05	0.000343	CcSEcCtD
Gliclazide—Headache—Hydrocortisone—systemic lupus erythematosus	4.09e-05	0.000342	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TNF—systemic lupus erythematosus	4.07e-05	0.00123	CbGpPWpGaD
Gliclazide—Dizziness—Triamcinolone—systemic lupus erythematosus	4.07e-05	0.00034	CcSEcCtD
Gliclazide—Dizziness—Methylprednisolone—systemic lupus erythematosus	4.06e-05	0.000339	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—JAK1—systemic lupus erythematosus	4.06e-05	0.00123	CbGpPWpGaD
Gliclazide—Infection—Methotrexate—systemic lupus erythematosus	4.04e-05	0.000337	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisone—systemic lupus erythematosus	4e-05	0.000335	CcSEcCtD
Gliclazide—Asthenia—Betamethasone—systemic lupus erythematosus	4e-05	0.000335	CcSEcCtD
Gliclazide—Asthenia—Dexamethasone—systemic lupus erythematosus	4e-05	0.000335	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—systemic lupus erythematosus	3.98e-05	0.000333	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—JAK1—systemic lupus erythematosus	3.98e-05	0.0012	CbGpPWpGaD
Gliclazide—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	3.98e-05	0.000333	CcSEcCtD
Gliclazide—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	3.97e-05	0.000332	CcSEcCtD
Gliclazide—Nausea—Prednisolone—systemic lupus erythematosus	3.97e-05	0.000332	CcSEcCtD
Gliclazide—Pruritus—Betamethasone—systemic lupus erythematosus	3.95e-05	0.00033	CcSEcCtD
Gliclazide—Pruritus—Dexamethasone—systemic lupus erythematosus	3.95e-05	0.00033	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—systemic lupus erythematosus	3.95e-05	0.00033	CcSEcCtD
Gliclazide—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	3.93e-05	0.000328	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—IL2—systemic lupus erythematosus	3.92e-05	0.00119	CbGpPWpGaD
Gliclazide—Vomiting—Triamcinolone—systemic lupus erythematosus	3.91e-05	0.000327	CcSEcCtD
Gliclazide—Vomiting—Methylprednisolone—systemic lupus erythematosus	3.9e-05	0.000326	CcSEcCtD
Gliclazide—Nausea—Hydrocortisone—systemic lupus erythematosus	3.88e-05	0.000324	CcSEcCtD
Gliclazide—Rash—Triamcinolone—systemic lupus erythematosus	3.88e-05	0.000324	CcSEcCtD
Gliclazide—Dermatitis—Triamcinolone—systemic lupus erythematosus	3.87e-05	0.000324	CcSEcCtD
Gliclazide—Rash—Methylprednisolone—systemic lupus erythematosus	3.87e-05	0.000324	CcSEcCtD
Gliclazide—Dermatitis—Methylprednisolone—systemic lupus erythematosus	3.87e-05	0.000323	CcSEcCtD
Gliclazide—Urticaria—Prednisone—systemic lupus erythematosus	3.86e-05	0.000323	CcSEcCtD
Gliclazide—Headache—Triamcinolone—systemic lupus erythematosus	3.85e-05	0.000322	CcSEcCtD
Gliclazide—Headache—Methylprednisolone—systemic lupus erythematosus	3.84e-05	0.000322	CcSEcCtD
Gliclazide—Body temperature increased—Prednisone—systemic lupus erythematosus	3.84e-05	0.000321	CcSEcCtD
Gliclazide—Abdominal pain—Prednisone—systemic lupus erythematosus	3.84e-05	0.000321	CcSEcCtD
Gliclazide—Diarrhoea—Betamethasone—systemic lupus erythematosus	3.82e-05	0.000319	CcSEcCtD
Gliclazide—Diarrhoea—Dexamethasone—systemic lupus erythematosus	3.82e-05	0.000319	CcSEcCtD
Gliclazide—Hypotension—Methotrexate—systemic lupus erythematosus	3.8e-05	0.000317	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—CDKN1B—systemic lupus erythematosus	3.75e-05	0.00113	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NAT2—systemic lupus erythematosus	3.75e-05	0.00113	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—TYK2—systemic lupus erythematosus	3.74e-05	0.00113	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2RA—systemic lupus erythematosus	3.72e-05	0.00112	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	3.71e-05	0.00112	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	3.7e-05	0.000309	CcSEcCtD
Gliclazide—Dizziness—Betamethasone—systemic lupus erythematosus	3.69e-05	0.000309	CcSEcCtD
Gliclazide—Dizziness—Dexamethasone—systemic lupus erythematosus	3.69e-05	0.000309	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—systemic lupus erythematosus	3.67e-05	0.000307	CcSEcCtD
Gliclazide—Nausea—Triamcinolone—systemic lupus erythematosus	3.65e-05	0.000306	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—systemic lupus erythematosus	3.65e-05	0.000305	CcSEcCtD
Gliclazide—Nausea—Methylprednisolone—systemic lupus erythematosus	3.65e-05	0.000305	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—NAT2—systemic lupus erythematosus	3.63e-05	0.0011	CbGpPWpGaD
Gliclazide—Dyspnoea—Methotrexate—systemic lupus erythematosus	3.62e-05	0.000303	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—systemic lupus erythematosus	3.61e-05	0.000302	CcSEcCtD
Gliclazide—Hypersensitivity—Prednisone—systemic lupus erythematosus	3.58e-05	0.000299	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—systemic lupus erythematosus	3.58e-05	0.000299	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—RXRA—systemic lupus erythematosus	3.56e-05	0.00108	CbGpPWpGaD
Gliclazide—Vomiting—Betamethasone—systemic lupus erythematosus	3.55e-05	0.000297	CcSEcCtD
Gliclazide—Vomiting—Dexamethasone—systemic lupus erythematosus	3.55e-05	0.000297	CcSEcCtD
Gliclazide—Rash—Betamethasone—systemic lupus erythematosus	3.52e-05	0.000294	CcSEcCtD
Gliclazide—Rash—Dexamethasone—systemic lupus erythematosus	3.52e-05	0.000294	CcSEcCtD
Gliclazide—Dermatitis—Betamethasone—systemic lupus erythematosus	3.52e-05	0.000294	CcSEcCtD
Gliclazide—Dermatitis—Dexamethasone—systemic lupus erythematosus	3.52e-05	0.000294	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—RASGRP1—systemic lupus erythematosus	3.51e-05	0.00106	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—TNF—systemic lupus erythematosus	3.51e-05	0.00106	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IFNG—systemic lupus erythematosus	3.51e-05	0.00106	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	3.51e-05	0.000293	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—systemic lupus erythematosus	3.5e-05	0.000293	CcSEcCtD
Gliclazide—Headache—Betamethasone—systemic lupus erythematosus	3.5e-05	0.000292	CcSEcCtD
Gliclazide—Headache—Dexamethasone—systemic lupus erythematosus	3.5e-05	0.000292	CcSEcCtD
Gliclazide—Asthenia—Prednisone—systemic lupus erythematosus	3.49e-05	0.000292	CcSEcCtD
Gliclazide—Pain—Methotrexate—systemic lupus erythematosus	3.47e-05	0.00029	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	3.46e-05	0.00105	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—CDKN1A—systemic lupus erythematosus	3.46e-05	0.00105	CbGpPWpGaD
Gliclazide—Pruritus—Prednisone—systemic lupus erythematosus	3.44e-05	0.000288	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—systemic lupus erythematosus	3.36e-05	0.00102	CbGpPWpGaD
Gliclazide—Feeling abnormal—Methotrexate—systemic lupus erythematosus	3.35e-05	0.00028	CcSEcCtD
Gliclazide—ALB—Hemostasis—ITGAX—systemic lupus erythematosus	3.34e-05	0.00101	CbGpPWpGaD
Gliclazide—Diarrhoea—Prednisone—systemic lupus erythematosus	3.33e-05	0.000278	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	3.32e-05	0.000278	CcSEcCtD
Gliclazide—Nausea—Dexamethasone—systemic lupus erythematosus	3.31e-05	0.000277	CcSEcCtD
Gliclazide—Nausea—Betamethasone—systemic lupus erythematosus	3.31e-05	0.000277	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TGFB1—systemic lupus erythematosus	3.3e-05	0.000998	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—F3—systemic lupus erythematosus	3.3e-05	0.000997	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—EP300—systemic lupus erythematosus	3.29e-05	0.000996	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL6—systemic lupus erythematosus	3.28e-05	0.000993	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—RXRA—systemic lupus erythematosus	3.24e-05	0.000981	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—F2—systemic lupus erythematosus	3.24e-05	0.000979	CbGpPWpGaD
Gliclazide—Urticaria—Methotrexate—systemic lupus erythematosus	3.23e-05	0.00027	CcSEcCtD
Gliclazide—Dizziness—Prednisone—systemic lupus erythematosus	3.21e-05	0.000269	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—systemic lupus erythematosus	3.21e-05	0.000269	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—systemic lupus erythematosus	3.21e-05	0.000269	CcSEcCtD
Gliclazide—Vomiting—Prednisone—systemic lupus erythematosus	3.09e-05	0.000258	CcSEcCtD
Gliclazide—Rash—Prednisone—systemic lupus erythematosus	3.06e-05	0.000256	CcSEcCtD
Gliclazide—Dermatitis—Prednisone—systemic lupus erythematosus	3.06e-05	0.000256	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—PPARG—systemic lupus erythematosus	3.05e-05	0.000922	CbGpPWpGaD
Gliclazide—Headache—Prednisone—systemic lupus erythematosus	3.04e-05	0.000255	CcSEcCtD
Gliclazide—Hypersensitivity—Methotrexate—systemic lupus erythematosus	2.99e-05	0.00025	CcSEcCtD
Gliclazide—ALB—Hemostasis—CLU—systemic lupus erythematosus	2.98e-05	0.000902	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MMP9—systemic lupus erythematosus	2.95e-05	0.000891	CbGpPWpGaD
Gliclazide—Asthenia—Methotrexate—systemic lupus erythematosus	2.91e-05	0.000244	CcSEcCtD
Gliclazide—Nausea—Prednisone—systemic lupus erythematosus	2.89e-05	0.000241	CcSEcCtD
Gliclazide—ALB—Hemostasis—P2RY12—systemic lupus erythematosus	2.89e-05	0.000873	CbGpPWpGaD
Gliclazide—Pruritus—Methotrexate—systemic lupus erythematosus	2.87e-05	0.00024	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—TLR9—systemic lupus erythematosus	2.86e-05	0.000866	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFA—systemic lupus erythematosus	2.86e-05	0.000865	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TNF—systemic lupus erythematosus	2.86e-05	0.000864	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IL6—systemic lupus erythematosus	2.83e-05	0.000857	CbGpPWpGaD
Gliclazide—Diarrhoea—Methotrexate—systemic lupus erythematosus	2.78e-05	0.000232	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—P2RY12—systemic lupus erythematosus	2.77e-05	0.000839	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—JAK1—systemic lupus erythematosus	2.72e-05	0.000824	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—systemic lupus erythematosus	2.72e-05	0.000824	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ALB—systemic lupus erythematosus	2.69e-05	0.000813	CbGpPWpGaD
Gliclazide—Dizziness—Methotrexate—systemic lupus erythematosus	2.69e-05	0.000225	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—TYK2—systemic lupus erythematosus	2.67e-05	0.000808	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SELE—systemic lupus erythematosus	2.66e-05	0.000804	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CSK—systemic lupus erythematosus	2.66e-05	0.000804	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—TGFB1—systemic lupus erythematosus	2.62e-05	0.000794	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	2.62e-05	0.000792	CbGpPWpGaD
Gliclazide—Vomiting—Methotrexate—systemic lupus erythematosus	2.58e-05	0.000216	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—NOS3—systemic lupus erythematosus	2.57e-05	0.000778	CbGpPWpGaD
Gliclazide—Rash—Methotrexate—systemic lupus erythematosus	2.56e-05	0.000214	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—systemic lupus erythematosus	2.56e-05	0.000214	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—CSK—systemic lupus erythematosus	2.55e-05	0.000772	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	2.55e-05	0.00077	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2RA—systemic lupus erythematosus	2.54e-05	0.00077	CbGpPWpGaD
Gliclazide—Headache—Methotrexate—systemic lupus erythematosus	2.54e-05	0.000213	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic lupus erythematosus	2.5e-05	0.000756	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ITGAM—systemic lupus erythematosus	2.5e-05	0.000755	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—LYN—systemic lupus erythematosus	2.41e-05	0.00073	CbGpPWpGaD
Gliclazide—Nausea—Methotrexate—systemic lupus erythematosus	2.41e-05	0.000202	CcSEcCtD
Gliclazide—ALB—Hemostasis—SH2B3—systemic lupus erythematosus	2.37e-05	0.000716	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NCF2—systemic lupus erythematosus	2.33e-05	0.000706	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—LYN—systemic lupus erythematosus	2.32e-05	0.000701	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL6—systemic lupus erythematosus	2.31e-05	0.000698	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SH2B3—systemic lupus erythematosus	2.27e-05	0.000688	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—TNF—systemic lupus erythematosus	2.27e-05	0.000687	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—F2—systemic lupus erythematosus	2.22e-05	0.00067	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2—systemic lupus erythematosus	2.18e-05	0.000659	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL6—systemic lupus erythematosus	2.16e-05	0.000652	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—systemic lupus erythematosus	2.1e-05	0.000636	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—RXRA—systemic lupus erythematosus	2.1e-05	0.000636	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—RXRA—systemic lupus erythematosus	2.04e-05	0.000616	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EP300—systemic lupus erythematosus	1.99e-05	0.000603	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—EP300—systemic lupus erythematosus	1.96e-05	0.000592	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL12—systemic lupus erythematosus	1.87e-05	0.000564	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNA1—systemic lupus erythematosus	1.86e-05	0.000563	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—systemic lupus erythematosus	1.83e-05	0.000554	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUNB—systemic lupus erythematosus	1.83e-05	0.000554	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—systemic lupus erythematosus	1.83e-05	0.000554	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RASGRP1—systemic lupus erythematosus	1.81e-05	0.000548	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RASGRP1—systemic lupus erythematosus	1.74e-05	0.000526	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TGFB1—systemic lupus erythematosus	1.73e-05	0.000524	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TGFB1—systemic lupus erythematosus	1.7e-05	0.000514	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PRL—systemic lupus erythematosus	1.69e-05	0.00051	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—systemic lupus erythematosus	1.62e-05	0.00049	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.52e-05	0.00046	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—systemic lupus erythematosus	1.49e-05	0.000451	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	1.45e-05	0.000437	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—JAK1—systemic lupus erythematosus	1.4e-05	0.000425	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.37e-05	0.000413	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JAK1—systemic lupus erythematosus	1.35e-05	0.000408	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—systemic lupus erythematosus	1.33e-05	0.000401	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2RA—systemic lupus erythematosus	1.31e-05	0.000397	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—systemic lupus erythematosus	1.31e-05	0.000395	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—systemic lupus erythematosus	1.29e-05	0.000389	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR5—systemic lupus erythematosus	1.28e-05	0.000387	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—systemic lupus erythematosus	1.27e-05	0.000384	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2RA—systemic lupus erythematosus	1.26e-05	0.000381	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—C3—systemic lupus erythematosus	1.25e-05	0.000378	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.24e-05	0.000377	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NAT2—systemic lupus erythematosus	1.21e-05	0.000366	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—systemic lupus erythematosus	1.19e-05	0.000361	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic lupus erythematosus	1.16e-05	0.000352	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—systemic lupus erythematosus	1.16e-05	0.00035	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—F2—systemic lupus erythematosus	1.14e-05	0.000345	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NOS3—systemic lupus erythematosus	1.14e-05	0.000345	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NOS3—systemic lupus erythematosus	1.11e-05	0.000335	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—F2—systemic lupus erythematosus	1.1e-05	0.000332	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NAT2—systemic lupus erythematosus	1.08e-05	0.000328	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CD80—systemic lupus erythematosus	1.05e-05	0.000318	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—systemic lupus erythematosus	1.04e-05	0.000316	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—systemic lupus erythematosus	1.01e-05	0.000306	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NAT2—systemic lupus erythematosus	9.89e-06	0.000299	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL2—systemic lupus erythematosus	9.78e-06	0.000296	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	9.6e-06	0.000291	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS3—systemic lupus erythematosus	9.07e-06	0.000274	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TYK2—systemic lupus erythematosus	8.88e-06	0.000269	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOS3—systemic lupus erythematosus	8.71e-06	0.000264	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—EP300—systemic lupus erythematosus	8.68e-06	0.000263	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	8.62e-06	0.000261	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—EP300—systemic lupus erythematosus	8.41e-06	0.000255	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	7.86e-06	0.000238	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	7.75e-06	0.000234	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—systemic lupus erythematosus	7.69e-06	0.000233	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	7.55e-06	0.000229	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1B—systemic lupus erythematosus	7.55e-06	0.000228	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—systemic lupus erythematosus	7.39e-06	0.000224	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	7.07e-06	0.000214	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—systemic lupus erythematosus	6.99e-06	0.000212	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—systemic lupus erythematosus	6.97e-06	0.000211	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EP300—systemic lupus erythematosus	6.9e-06	0.000209	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	6.78e-06	0.000205	CbGpPWpGaD
Gliclazide—ALB—Metabolism—RXRA—systemic lupus erythematosus	6.77e-06	0.000205	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EP300—systemic lupus erythematosus	6.63e-06	0.000201	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—systemic lupus erythematosus	6.54e-06	0.000198	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	6.28e-06	0.00019	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	6.18e-06	0.000187	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RXRA—systemic lupus erythematosus	6.08e-06	0.000184	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—systemic lupus erythematosus	6e-06	0.000181	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—systemic lupus erythematosus	5.76e-06	0.000174	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	5.64e-06	0.000171	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RXRA—systemic lupus erythematosus	5.54e-06	0.000168	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	5.14e-06	0.000156	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—systemic lupus erythematosus	4.34e-06	0.000131	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—systemic lupus erythematosus	4.28e-06	0.000129	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—systemic lupus erythematosus	3.84e-06	0.000116	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NOS3—systemic lupus erythematosus	3.68e-06	0.000111	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—systemic lupus erythematosus	3.5e-06	0.000106	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—systemic lupus erythematosus	3.45e-06	0.000104	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—systemic lupus erythematosus	3.36e-06	0.000102	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NOS3—systemic lupus erythematosus	3.3e-06	9.99e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—systemic lupus erythematosus	3.15e-06	9.52e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—systemic lupus erythematosus	3.02e-06	9.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NOS3—systemic lupus erythematosus	3.01e-06	9.11e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—EP300—systemic lupus erythematosus	2.8e-06	8.46e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—systemic lupus erythematosus	2.75e-06	8.33e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EP300—systemic lupus erythematosus	2.51e-06	7.6e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EP300—systemic lupus erythematosus	2.29e-06	6.93e-05	CbGpPWpGaD
